We report the molecular characteristics of nine YST patients with successful molecular analysis leading to potentially targetable oncogenic mutations identified for three patients (33.3% of all patients) in KRAS, KIT and ARID1A. Actionability is defined as a molecular alteration for which there is clinical or preclinical evidence of a predictive benefit from a specific therapy (in any cancer type). This evidence concerns the gene ARID1A and cancer.